1. Williams C, Coyle D, Gray A, et al. European School of Oncology advisory report to the Commission of the European Communities for the ‘Europe Against Cancer Programme’: cost-effectiveness in cancer care. Eur J Cancer 1995; 31: 1410–24
2. Drummond MF. Cost-effectiveness guidelines for reimbursment of pharmaceuticals: is economic evaluation ready for its enhanced status? Health Econ 1992; 1: 85–92
3. Jönsson B, Karlsson G. Economic evaluation of cancer treatments. In: Williams CJ, editor. Introducing new treatments for cancer: practical, ethical and legal problems. New York (NY): John Wiley & Son, 1992: 237–65
4. Kinney MC, Lukens JN. Classification and differentiation of the acute leukemias. In: Lee RG, Foerster J, Lukens J, et al., editors. Winthrobe’s clinical hematology. Baltimore (MD): Williams & Wilkins, 1998: 2209–40
5. Greer JP, Bear MR, Kinney MC. Acute myelogenous leukemia. In: Lee GR, Foerster J, Lukens J, et al., editors. Wintrobe’s clinical hematology. Baltimore (MD): Williams & Wilkins, 1998: 2272–319